Physician
Oncology
Dr. David R. Spigel, MD
|
|
Give Review
David Spigel works in the field of Oncology. He studied medicine at Indiana University School of Medicine. Indiana University School of Medicine has a rank of 45 in research and a 47 in primary care He has 1 awards "Regional Top Doctor". Dr. David R. Spigel is a published doctor and has 86 publications published. The lastest was: 'Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Pemetrexed clinical studies in performance status 2 patients with non-small cell lung Cancer (Review).
- Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay.
- Quality of life Analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizum...
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung Cancer.
- Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Pa...
- PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizu...
- Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metasta...
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory m...
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer.
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carbo...
- Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology.
- Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches.
- Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Ph...
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic Carcinoma of the pancreas: A Sarah Cannon Research Institute phase II...
- PARP Inhibitors in Lung Cancer.
- Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotin...
- Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung Cancer.
- Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with Carcinoma of unknown primary site: a prospective ...
- Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung Cancer.
- Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung Cancer.
- Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
- Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First-Line Treatment for Patients With Glioblastoma.
- A Phase I Trial of Vatalanib (PTK/ZK) in Combination With Bevacizumab in Patients With Refractory and/or Advanced Malignancies.
- Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Sma...
- A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced N...
- Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck:...
- Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer.
- Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanc...
- A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metast...
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer.
- A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer.
- Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung Cancer: results from the SALUTE trial.
- A pilot study of adjuvant Doxorubicin and cyclophosphamide followed by Paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast Cancer.
- A phase I study of panobinostat in combination with gemcitabine in the treatment of solid Tumors.
- Bevacizumab and everolimus in the treatment of patients with metastatic Melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal Cancer.
- Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung Cancer.
- A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung Cancer.
- Phase II trial of vinflunine in relapsed small cell lung Cancer.
- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung Cancer.
- Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory Carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology ...
- Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized Carcinoma of the esophagus or gastroesophageal...
- Phase II trial of bevacizumab and everolimus in patients with advanced renal cell Carcinoma.
- Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung Cancer.
- Tracheoesophageal fistula formation in patients with lung Cancer treated with chemoradiation and bevacizumab.
- Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with Carcinoma of unknown primary site: a randomized, phase III ...
- Molecular profiling in unknown primary Cancer: accuracy of tissue of origin prediction.
- A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
- Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung Cancer.
- Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with Carcinoma of unknown primary site.
- A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle ...
- Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast Cancer.
- A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast Cancer.
- Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast Cancer.
- Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin Lymphoma: a pha...
- Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous Carcinoma of the head an...
- Neuroendocrine Carcinoma of unknown primary site.
- Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast Cancer.
- A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast Cancer.
- Molecular profiling of Carcinoma of unknown primary and correlation with clinical evaluation.
- Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
- Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung Cancer.
- A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high...
- Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic Leukemia or small lymphocyt...
- What is the role of novel taxanes in non-small-cell lung Cancer?
- Treatment of advanced renal cell Carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
- Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung Cancer: a randomized pha...
- Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung Cancer: a phase II/III study of the Minnie Pearl Cancer Research Netw...
- High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
- Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate Cancer: a Minnie Pearl Cancer Research Network phase II trial.
- Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
- Docetaxel and epirubicin as first-line treatment for patients with metastatic breast Cancer: a Minnie Pearl Cancer Research Network Phase II trial.
- Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate Cancer: a phase II tri...
- Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Netwo...
- Treatment of metastatic renal cell Carcinoma with a combination of bevacizumab and erlotinib.
- Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung Cancer: a Minnie Pearl Cancer Research Network randomized, prospective...
- Single-agent gefitinib in patients with untreated advanced non-small-cell lung Cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
- Does this patient have a family history of Cancer? An evidence-based analysis of the accuracy of family Cancer history.
- Trastuzumab regimens for HER2-overexpressing metastatic breast Cancer.
- Evolving role of irinotecan in small-cell lung Cancer.
- Chemotherapy in metastatic and locally advanced non-small cell lung Cancer.
- HER2 overexpressing metastatic breast Cancer.
Schools
University Of Tennessee Health Science Center College Of Medicine
Indiana University Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Indiana University School of Medicine -
University of Tennessee College of Medicine
Drug Facts
| NPI NUMBER | 1427074210 | |
| NPPES Provider LastName | SPIGEL | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 372031632 | |
| NPPES Provider State | TN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1074.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 168.0 | |
| Percent Opioid Claims | 15.64 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427074210 |
| Last Name Of The Provider | SPIGEL |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Todd M. Bauer, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Howard A. Burris III, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Carlos L. Arteaga, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Christina L. Derleth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine M. Lovly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan B. Sandler, MD |